Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema Intellia Therapeutics has reported positive Phase 3 results for lonvoguran ziclumeran in hereditary angioedema, marking what it said is the first successful late-stage tr... See more
Myomaker Bio, a UK biotechnology company spun out from Loughborough University, has launched a lab-grown human skeletal muscle platform designed to improve preclinical drug testing and reduce reliance on animal models. The company has developed engineered... See more
Abivax will present nine scientific abstracts on obefazimod at Digestive Disease Week 2026, highlighting Phase 3 data in ulcerative colitis as the French biotech seeks to strengthen the profile of its lead inflammatory bowel disease candidate. The present... See more
NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains Nature publishes Phase 1b data showing NETRIS Pharma’s NP137 improves survival and surgery conversion in locally advanced pancreatic cancer. NETRIS Pha... See more
Viz.ai, Johnson & Johnson strike US chronic subdural hematoma AI deal Viz.ai has entered a collaboration with Johnson & Johnson to expand access in the United States to software designed to help detect chronic subdural hematoma and support treatme... See more
